This federal contract award is for the delivery of the pharmaceutical product ORLADEYO (berotralstat) to the Department of Veterans Affairs (VA) through the Veterans Integrated Service Network 20 (VISN 20). The prime contractor is Biocryst Pharmaceuticals Inc., a biotechnology company that specializes in developing small molecule drugs for rare diseases. The contract is a delivery order under Biocryst's Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs, which has a ceiling value of $1.25 million and an ultimate completion date of May 14, 2026. The specific award has a ceiling value of $394,853.42 and is a firm fixed-price contract. The contract does not have a set-aside designation, indicating that Biocryst competes for awards in the open market without small business or other preferential status. Biocryst Pharmaceuticals is also the holder of a $10 million Blanket Purchase Agreement (BPA) with the VA for the expedited procurement of ORLADEYO and RAPIVAB (peramivir), another Biocryst pharmaceutical product used for influenza treatment.
Generated 2/12/25, 9:01 AM